Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Berzofsky Website

Jay A. Berzofsky, M.D., Ph.D.

Selected Publications
1)  Berzofsky JA, Terabe M.
A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity.
Cancer Immunol. Immunother. 2008. [Journal]
2)  Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ.
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.
Clin. Cancer Res. 14: 4850-8, 2008. [Journal]
3)  Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.
Cancer Res. 68: 3835-43, 2008. [Journal]
4)  Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B.
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.
Virology. 372: 260-72, 2008. [Journal]
5)  Dzutsev AK, Belyakov IM, Isakov DV, Gagnon SJ, Margulies DH, Berzofsky JA.
Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay.
J. Immunol. Methods. 333: 71-8, 2008. [Journal]
6)  Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA.
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.
Proc. Natl. Acad. Sci. U.S.A. 105: 5201-6, 2008. [Journal]
7)  Terabe M, Tagaya Y, Zhu Q, Granger L, Roederer M, Waldmann TA, Berzofsky JA.
IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells.
J. Immunol. 180: 7276-86, 2008. [Journal]
8)  Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA.
Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation.
Cancer Immunol. Immunother. 57: 907-912, 2008. [Journal]
9)  Berzofsky JA, Terabe M.
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis.
J. Immunol. 180: 3627-35, 2008. [Journal]
10)  Ambrosino E, Berzofsky JA, Terabe M.
Regulation of tumor immunity: the role of NKT cells.
Expert Opin Biol Ther. 8: 725-34, 2008. [Journal]
11)  Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W.
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.
Cancer Res. 68: 3467-75, 2008. [Journal]
12)  Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, Berzofsky J, Reiter Y.
Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
Eur. J. Immunol. 38: 1706-20, 2008. [Journal]
13)  Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC, Berzofsky JA.
Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
Cancer Res. 68: 1979-87, 2008. [Journal]
14)  Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.
Cancer Res. 68: 3915-23, 2008. [Journal]
15)  Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA.
A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells.
J. Immunol. 178: 7211-21, 2007. [Journal]
16)  Dzutsev AH, Belyakov IM, Isakov DV, Margulies DH, Berzofsky JA.
Avidity of CD8 T cells sharpens immunodominance.
Int. Immunol. 19: 497-507, 2007. [Journal]
17)  Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, Yamamura T, Kumar V, Berzofsky JA.
Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis.
J. Immunol. 179: 5126-36, 2007. [Journal]
18)  Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh S.
Development of Smallpox Vaccine Candidates with Integrated IL-15 that Demonstrate Superior Immunogenicity, Efficacy and Safety in Mice.
J Virol. 81: 8774-8783, 2007. Full Text Article. [Journal]
19)  Ota MO, Ndhlovu Z, Oh S, Piyasirisilp S, Berzofsky JA, Moss WJ, Griffin DE.
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination.
J. Infect. Dis. 195: 1799-807, 2007. [Journal]
20)  Terabe M, Berzofsky JA.
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.
Trends Immunol. 28: 491-6, 2007. [Journal]
21)  Belyakov IM, Kozlowski S, Mage M, Ahlers JD, Boyd LF, Margulies DH, Berzofsky JA.
Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs.
Int. Immunol. 19: 1413-20, 2007. [Journal]
22)  Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA, Khleif SN.
The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.
Vaccine. 25: 5882-91, 2007. [Journal]
23)  Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ, Berzofsky JA.
CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
Cancer Res. 66: 3869-75, 2006. [Journal]
24)  Pinto LA, Viscidi R, Harro CD, Kemp TJ, Garcia-Pineres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A.
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Virology. 353: 451-62, 2006. [Journal]
25)  Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK.
Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
Cancer Res. 66: 4434-42, 2006. [Journal]
26)  Qian J, Dong Y, Pang YY, Ibrahim R, Berzofsky JA, Schiller JT, Khleif SN.
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Int. J. Cancer. 118: 3022-9, 2006. [Journal]
27)  Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Klinman D, Berzofsky JA.
Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host.
J. Immunol. 177: 6336-43, 2006. [Journal]
28)  Okazaki T, Pendleton CD, Sarobe P, Thomas EK, Iyengar S, Harro C, Schwartz D, Berzofsky JA.
Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine.
J Immunol. 176: 3753-9, 2006. [Journal]
29)  van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA.
Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors.
Cancer Res. 66: 1818-23, 2006. [Journal]
30)  Dong Y, Qian J, Ibrahim R, Berzofsky JA, Khleif SN.
Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.
J Immunother. 29: 32-40, 2006. [Journal]
31)  Belyakov IM, Kuznetsov VA, Kelsall B, Klinman D, Moniuszko M, Lemon M, Markham PD, Pal R, Clements JD, Lewis MG, Strober W, Franchini G, Berzofsky JA.
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
Blood. 107: 3258-64, 2006. [Journal]
32)  Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK.
Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Clin. Cancer Res. 12: 4678-86, 2006. [Journal]
33)  Garcia-Pineres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, Ramirez M, Villegas M, Schiffman M, Rodriguez AC, Burk RD, Hildesheim M, Freer E, Bonilla J, Bratti C, Berzofsky JA, Pinto LA.
Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women.
Cancer Res. 66: 11070-6, 2006. [Journal]
34)  Okazaki T, Terabe M, Catanzaro AT, Pendleton CD, Yarchoan R, Berzofsky JA.
Possible therapeutic vaccine strategy against HIV escape from RT inhibitor studied in HLA-A2 transgenic mice.
J Virol. 80: 10645-10651, 2006. Full Text Article. [Journal]
35)  Oh S, Stegman B, Pendleton CD, Ota MO, Pan CH, Griffin DE, Burke DS, Berzofsky JA.
Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus.
Virology. 352: 390-9, 2006. [Journal]
36)  Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G.
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.
J Virol. 80: 3732-42, 2006. [Journal]
37)  Kotelkin A, Belyakov IM, Yang L, Berzofsky JA, Collins PL, Bukreyev A.
The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.
J. Virol. 80: 5958-67, 2006. [Journal]
38)  Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA.
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.
J Exp Med. 202: 1627-33, 2005. [Journal]
39)  Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA.
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
J Immunol. 174: 4228-36, 2005. [Journal]
40)  Bukreyev A, Belyakov IM, Prince GA, Yim KC, Harris KK, Berzofsky JA, Collins PL.
Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
J Virol. 79: 9515-26, 2005. [Journal]
41)  Pinto LA, Trivett MT, Wallace D, Higgins J, Baseler M, Terabe M, Belyakov IM, Berzofsky JA, Hildesheim A.
Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry.
Cytometry B Clin Cytom. 63: 47-55, 2005. [Journal]
42)  Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, Berzofsky JA, Hildesheim A.
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
Vaccine. 23: 3555-64, 2005. [Journal]
43)  Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA.
Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome.
J Clin Oncol. 23: 5099-107, 2005. [Journal]
44)  Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL.
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
Nat Med. 11: 1238-43, 2005. [Journal]
45)  Berzofsky JA, Oh S, Terabe M.
Peptide vaccines against cancer.
Cancer Treat. Res. 123: 115-36, 2005. [Journal]
46)  Wang YE, Zhang C, Berzofsky J, DeLisi C.
Selecting stable molecular targets for treatment and prevention of AIDS.
Genome informatics. International Conference on Genome Informatics. 16: 254-61, 2005. [Journal]
47)  Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ.
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
J. Exp. Med. 201: 139-48, 2005. [Journal]
48)  Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA.
Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.
Int J Cancer. 114: 80-7, 2005. [Journal]
49)  Kuznetsov VA, Stepanov VS, Berzofsky JA, Belyakov IM.
Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV.
J Clin Virol. 31 Suppl 1: S69-82, 2004. [Journal]
50)  De Groot AS, Berzofsky JA.
From genome to vaccine--new immunoinformatics tools for vaccine design.
Methods. 34: 425-8, 2004. [Journal]
51)  Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.
Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
Cancer Res. 64: 2610-8, 2004. [Journal]
52)  Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA.
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.
Proc Natl Acad Sci U S A. 101: 15154-9, 2004. [Journal]
53)  Belyakov IM, Berzofsky JA.
Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.
Immunity. 20: 247-53, 2004. [Journal]
54)  Terabe M, Berzofsky JA.
Immunoregulatory T cells in tumor immunity.
Curr Opin Immunol. 16: 157-62, 2004. [Journal]
55)  Belyakov IM, Ahlers JD, Berzofsky JA.
Mucosal AIDS vaccines: current status and future directions.
Expert Rev Vaccines. 3 Suppl 1: S65-73, 2004. [Journal]
56)  Lee WJ, Cantor KP, Berzofsky JA, Zahm SH, Blair A.
Non-Hodgkin's lymphoma among asthmatics exposed to pesticides.
Int J Cancer. 111: 298-302, 2004. [Journal]
57)  Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM.
Progress on new vaccine strategies against chronic viral infections.
J Clin Invest. 114: 450-62, 2004. [Journal]
58)  Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC.
Progress on new vaccine strategies for the immunotherapy and prevention of cancer.
J Clin Invest. 113: 1515-25, 2004. [Journal]
59)  Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA.
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
J Virol. 78: 7052-60, 2004. [Journal]
60)  Terabe M, Park JM, Berzofsky JA.
Role of IL-13 in regulation of anti-tumor immunity and tumor growth.
Cancer Immunol Immunother. 53: 79-85, 2004. [Journal]
61)  Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA.
Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.
J Clin Invest. 113: 998-1007, 2004. [Journal]
62)  Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.
Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Cancer Res. 64: 8022-8, 2004. [Journal]
63)  Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
J Infect Dis. 188: 327-38, 2003. [Journal]
64)  Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP.
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.
Proc Natl Acad Sci U S A. 100: 3392-7, 2003. [Journal]
65)  Ahlers JD, Belyakov IM, Berzofsky JA.
Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.
Curr Mol Med. 3: 285-301, 2003. [Journal]
66)  Okazaki T, Pendleton CD, Lemonnier F, Berzofsky JA.
Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
J Immunol. 171: 2548-55, 2003. [Journal]
67)  Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA.
Selective induction of high avidity CTL by altering the balance of signals from APC.
J Immunol. 170: 2523-30, 2003. [Journal]
68)  Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA.
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.
Proc Natl Acad Sci U S A. 100: 9458-63, 2003. [Journal]
69)  Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA.
Transforming Growth Factor-b production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T Lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
J Exp Med. 198: 1741-1752, 2003. [Journal]
70)  Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA.
A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L.
Proc Natl Acad Sci USA. 99: 13020-13025, 2002. [Journal]
71)  Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW.
DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses.
Blood. 100: 1153-1159, 2002. [Journal]
72)  Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL.
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.
Med Pediatr Oncol. 38: 158-164, 2002. [Journal]
73)  Takahashi M, Osono E, Nakagawa Y, Wang J, Berzofsky JA, Margulies DH, Takahashi H.
Rapid induction of apoptosis in CD8+ HIV-1 envelope-specific murine CTLs by short exposure to antigenic peptide.
J Immunol. 169: 6588-93, 2002. [Journal]
74)  Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK.
Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
J Immunol. 169: 5796-804, 2002. [Journal]
75)  Berzofsky J.
Immunogenicity and antigenicity. In: Samter's Immunologic Diseases. Volume 6th edition.
Baltimore: Lippincott Williams & Wilkins; 2001. p. Chapter 7: 65-82 [Book Chapter]
76)  Derby MA, Snyder JT, Tse R, Alexander-Miller MA, Berzofsky JA.
An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8+ CTL.
Eur J Immunol. 31: 2951-2959, 2001. [Journal]
77)  Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA.
Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.
Cancer Res. 61: 6868-6875, 2001. [Journal]
78)  Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA.
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
J Clin Oncol. 19: 1848-1854, 2001. [Journal]
79)  Chung DH, Belyakov IM, Derby MA, Wang J, Boyd LF, Berzofsky JA, Margulies DH.
Competitive inhibition in vivo and skewing of the T cell repertoire of antigen-specific CTL priming by an anti-peptide-MHC monoclonal antibody.
J Immunol. 167: 699-707, 2001. [Journal]
80)  Takahashi M, Nakagawa Y, Berzofsky JA, Takahashi H.
Counter-regulation of cytolytic activity and cytokine production in HIV-1-specific murine CD8+ cytotoxic T lymphocytes by free antigenic peptide.
Int Immunol. 13: 43-51, 2001. [Journal]
81)  Berzofsky JA.
Design of engineered vaccines for systemic and mucosal immunity to HIV.
Pathol Biol (Paris). 49: 466-467, 2001. [Journal]
82)  Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, Kopp W, Mackall CL, Berzofsky J, Read EJ.
Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.
Cytotherapy. 3: 19-29, 2001. [Journal]
83)  Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL.
Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.
J Virol. 75: 12128-12140, 2001. [Journal]
84)  Ahlers JD, Belyakov IM, Thomas EK, Berzofsky JA.
High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.
J Clin Invest. 108: 1677-1685, 2001. [Journal]
85)  Derby M, Alexander-Miller M, Tse R, Berzofsky J.
High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.
J Immunol. 166: 1690-1697, 2001. [Journal]
86)  Horner AA, Datta SK, Takabayashi K, Belyakov IM, Hayashi T, Cinman N, Nguyen MD, Van Uden JH, Berzofsky JA, Richman DD, Raz E.
Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites.
J Immunol. 167: 1584-1591, 2001. [Journal]
87)  Shirai M, Fujinaga R, Masaki T, Berzofsky JA.
Impaired development of HIV-1 gp160-specific CD8(+) cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with Helicobacter pylori infection.
Eur J Immunol. 31: 516-526, 2001. [Journal]
88)  Hel Z, Nacsa J, Kelsall B, Tsai WP, Letvin N, Parks RW, Tryniszewska E, Picker L, Lewis MG, Edghill-Smith Y, Moniuszko M, Pal R, Stevceva L, Altman JD, Allen TM, Watkins D, Torres JV, Berzofsky JA, Belyakov IM, Strober W, Franchini G.
Impairment of Gag-specific CD8(+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques.
J Virol. 75: 11483-11495, 2001. [Journal]
89)  Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA.
Mechanisms of cytokine synergy essential for vaccine protection against viral challenge.
Int Immunol. 13: 897-908, 2001. [Journal]
90)  Marshall MA, Jankovic D, Maher VE, Sher A, Berzofsky JA.
Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor.
Microbes Infect. 3: 1051-1061, 2001. [Journal]
91)  Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, Berzofsky JA.
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.
Nat Med. 7: 1320-1326, 2001. [Journal]
92)  McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, Schnell MJ.
Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.
J Virol. 75: 4430-4434, 2001. [Journal]
93)  Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA.
Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-alpha synergize for IL-12R expression at low antigen dose.
Int Immunol. 13: 1433-1442, 2001. [Journal]
94)  Berzofsky JA, Ahlers JD, Belyakov IM.
Strategies for designing and optimizing new generation vaccines.
Nat Rev Immunol. 1: 209-219, 2001. [Journal]
95)  Derby MA, Wang J, Margulies DH, Berzofsky JA.
Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining.
Int Immunol. 13: 817-824, 2001. [Journal]
96)  Berzofsky J, Helman L, Carbone D.
Oncogene products and mutated proteins as tumor antigens. In: Biologic Therapy of Cancer: Principles and Practice. Volume 3rd edition.
Baltimore: Lippincott, Williams & Wilkins; 2000. p. 944 [Book Chapter]
97)  Nakagawa Y, Takeshita T, Berzofsky JA, Takahashi H.
Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes.
Immunology. 101: 76-82, 2000. [Journal]
98)  Polakova K, Plaksin D, Chung DH, Belyakov IM, Berzofsky JA, Margulies DH.
Antibodies directed against the MHC-I molecule H-2Dd complexed with an antigenic peptide: similarities to a T cell receptor with the same specificity.
J Immunol. 165: 5703-5712, 2000. [Journal]
99)  Parra M, Hui G, Johnson AH, Berzofsky JA, Roberts T, Quakyi IA, Taylor DW.
Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1.
Infect Immun. 68: 2685-2691, 2000. [Journal]
100)  Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA.
Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.
J Immunol. 165: 6454-6462, 2000. [Journal]
101)  Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA.
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
Nat Immunol. 1: 515-520, 2000. [Journal]
102)  Grene E, Newton DA, Brown EA, Berzofsky JA, Gattoni-Celli S, Shearer GM.
Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes.
AIDS. 14: 1497-1506, 2000. [Journal]
103)  Mackall C, Berzofsky J, Helman LJ.
Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy.
Clin Orthop. (373) 25-31, 2000. [Journal]
104)  Berzofsky J, Berkower I, Epstein S.
Antigen-antibody interactions and monoclonal antibodies. In: Fundamental Immunology. Volume 4th edition.
Baltimore: Lippincott Williams & Wilkins; 1999. p. 75-110 [Book Chapter]
105)  Berzofsky J, Berkower I.
Immunogenicity and antigen structure. In: Fundamental Immunology. Volume 4th edition.
Baltimore: Lippincott Williams & Wilkins; 1999. p. 651-699 [Book Chapter]
106)  Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA.
A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
J Immunol. 163: 184-193, 1999. [Journal]
107)  Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM.
Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.
Immunol Rev. 170: 151-172, 1999. [Journal]
108)  McDyer JF, Dybul M, Goletz TJ, Kinter AL, Thomas EK, Berzofsky JA, Fauci AS, Seder RA.
Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms.
J Immunol. 162: 3711-3717, 1999. [Journal]
109)  D'Amico R, Pinto LA, Meyer P, Landay AL, Harris AA, Clerici M, Berzofsky JA, Shearer GM, Kessler HA.
Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers.
Infect Control Hosp Epidemiol. 20: 428-430, 1999. [Journal]
110)  Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R.
HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients.
AIDS. 13: 2003-2012, 1999. [Journal]
111)  Suh WK, Derby MA, Cohen-Doyle MF, Schoenhals GJ, Früh K, Berzofsky JA, Williams DB.
Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain alpha3 domain.
J Immunol. 162: 1530-1540, 1999. [Journal]
112)  Ciernik IF, Romero P, Berzofsky JA, Carbone DP.
Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope.
Int J Radiat Oncol Biol Phys. 45: 735-741, 1999. [Journal]
113)  Belyakov IM, Moss B, Strober W, Berzofsky JA.
Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
Proc Natl Acad Sci U S A. 96: 4512-4517, 1999. [Journal]
114)  Oscherwitz J, Gotch FM, Cease KB, Berzofsky JA.
New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design.
AIDS. 13 Suppl A: S163-S174, 1999. [Journal]
115)  Chung DH, Dorfman J, Plaksin D, Natarajan K, Belyakov IM, Hunziker R, Berzofsky JA, Yokoyama WM, Mage MG, Margulies DH.
NK and CTL recognition of a single chain H-2Dd molecule: distinct sites of H-2Dd interact with NK and TCR.
J Immunol. 163: 3699-3708, 1999. [Journal]
116)  Shirai M, Arichi T, Chen M, Masaki T, Nishioka M, Ikeda K, Takahashi H, Enomoto N, Saito T, Major ME, Nakazawa T, Akatsuka T, Feinstone SM, Berzofsky JA.
T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region.
J Immunol. 162: 568-576, 1999. [Journal]
117)  Tian JH, Good MF, Hirunpetcharat C, Kumar S, Ling IT, Jackson D, Cooper J, Lukszo J, Coligan J, Ahlers J, Saul A, Berzofsky JA, Holder AA, Miller LH, Kaslow DC.
Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria.
Parasite Immunol. 20: 263-278, 1998. [Journal]
118)  Sarobe P, Pendleton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM, Berzofsky JA.
Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.
J Clin Invest. 102: 1239-1248, 1998. [Journal]
119)  Belyakov IM, Wyatt LS, Ahlers JD, Earl P, Pendleton CD, Kelsall BL, Strober W, Moss B, Berzofsky JA.
Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.
J Virol. 72: 8264-8272, 1998. [Journal]
120)  Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, Strober W, Berzofsky JA.
Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.
Proc Natl Acad Sci U S A. 95: 1709-1714, 1998. [Journal]
121)  Shirai M, Arichi T, Nakazawa T, Berzofsky JA.
Persistent infection by Helicobacter pylori down-modulates virus-specific CD8+ cytotoxic T cell response and prolongs viral infection.
J Infect Dis. 177: 72-80, 1998. [Journal]
122)  Alexander-Miller MA, Derby MA, Sarin A, Henkart PA, Berzofsky JA.
Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes.
J Exp Med. 188: 1391-1399, 1998. [Journal]
123)  Belyakov IM, Ahlers JD, Brandwein BY, Earl P, Kelsall BL, Moss B, Strober W, Berzofsky JA.
The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.
J Clin Invest. 102: 2072-2081, 1998. [Journal]
124)  Leggatt GR, Hosmalin A, Pendleton CD, Kumar A, Hoffman S, Berzofsky JA.
The importance of pairwise interactions between peptide residues in the delineation of TCR specificity.
J Immunol. 161: 4728-4735, 1998. [Journal]
125)  Hirunpetcharat C, Tian JH, Kaslow DC, van Rooijen N, Kumar S, Berzofsky JA, Miller LH, Good MF.
Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen.
J Immunol. 159: 3400-3411, 1997. [Journal]
126)  Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA.
Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes.
J Immunol. 158: 3947-3958, 1997. [Journal]
127)  Leggatt GR, Alexander-Miller MA, Kumar A, Hoffman SL, Berzofsky JA.
Cytotoxic T lymphocyte (CTL) adherence assay (CAA): a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes.
J Immunol Methods. 201: 1-10, 1997. [Journal]
128)  Shirai M, Kozlowski S, Margulies DH, Berzofsky JA.
Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop.
J Immunol. 158: 3181-3188, 1997. [Journal]
129)  Goletz TJ, Klimpel KR, Leppla SH, Keith JM, Berzofsky JA.
Delivery of antigens to the MHC class I pathway using bacterial toxins.
Hum Immunol. 54: 129-136, 1997. [Journal]
130)  Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA.
Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence.
Proc Natl Acad Sci U S A. 94: 10856-10861, 1997. [Journal]
131)  Hildesheim A, Schiffman MH, Tsukui T, Swanson CA, Lucci J, Scott DR, Glass AG, Rush BB, Lorincz AT, Corrigan A, Burk RD, Helgesen K, Houghten RA, Sherman ME, Kurman RJ, Berzofsky JA, Kramer TR.
Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Cancer Epidemiol Biomarkers Prev. 6: 807-813, 1997. [Journal]
132)  Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM.
Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood.
Am J Med. 102: 21-24, 1997. [Journal]
133)  Kozhich AT, Caspi RR, Berzofsky JA, Gery I.
Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution.
J Immunol. 158: 4145-4151, 1997. [Journal]
134)  Smith MC, Pendleton CD, Maher VE, Kelley MJ, Carbone DP, Berzofsky JA.
Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing.
Int Immunol. 9: 1085-1093, 1997. [Journal]
135)  Saito T, Sherman GJ, Kurokohchi K, Guo ZP, Donets M, Yu MY, Berzofsky JA, Akatsuka T, Feinstone SM.
Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice.
Gastroenterology. 112: 1321-1330, 1997. [Journal]
136)  Sarin A, Williams MS, Alexander-Miller MA, Berzofsky JA, Zacharchuk CM, Henkart PA.
Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases.
Immunity. 6: 209-215, 1997. [Journal]
137)  Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA.
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.
Proc Natl Acad Sci U S A. 94: 12059-12064, 1997. [Journal]
138)  Zhang C, Cornette JL, Berzofsky JA, DeLisi C.
The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design.
Vaccine. 15: 1291-1302, 1997. [Journal]
139)  Clerici M, Sarin A, Berzofsky JA, Landay AL, Kessler HA, Hashemi F, Hendrix CW, Blatt SP, Rusnak J, Dolan MJ, Coffman RL, Henkart PA, Shearer GM.
Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin.
AIDS. 10: 603-611, 1996. [Journal]
140)  Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, Berzofsky JA.
Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization.
AIDS Res Hum Retroviruses. 12: 259-272, 1996. [Journal]
141)  Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP.
Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
Cell Immunol. 170: 111-119, 1996. [Journal]
142)  Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA.
Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma.
Hepatology. 23: 1181-1188, 1996. [Journal]
143)  Tian JH, Miller LH, Kaslow DC, Ahlers J, Good MF, Alling DW, Berzofsky JA, Kumar S.
Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine.
J Immunol. 157: 1176-1183, 1996. [Journal]
144)  Beretta A, Weiss SH, Rappocciolo G, Mayur R, De Santis C, Quirinale J, Cosma A, Robbioni P, Shearer GM, Berzofsky JA.
Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope.
J Infect Dis. 173: 472-476, 1996. [Journal]
145)  Ciernik IF, Berzofsky JA, Carbone DP.
Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes.
Clin Cancer Res. 2: 877-882, 1996. [Journal]
146)  Landay AL, Clerici M, Hashemi F, Kessler H, Berzofsky JA, Shearer GM.
In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10.
J Infect Dis. 173: 1085-1091, 1996. [Journal]
147)  Takahashi H, Nakagawa Y, Leggatt GR, Ishida Y, Saito T, Yokomuro K, Berzofsky JA.
Inactivation of human immunodeficiency virus (HIV)-1 envelope-specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism.
J Exp Med. 183: 879-889, 1996. [Journal]
148)  Ciernik IF, Berzofsky JA, Carbone DP.
Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.
J Immunol. 156: 2369-2375, 1996. [Journal]
149)  Tsukui T, Hildesheim A, Schiffman MH, Lucci J, Contois D, Lawler P, Rush BB, Lorincz AT, Corrigan A, Burk RD, Qu W, Marshall MA, Mann D, Carrington M, Clerici M, Shearer GM, Carbone DP, Scott DR, Houghten RA, Berzofsky JA.
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.
Cancer Res. 56: 3967-3974, 1996. [Journal]
150)  Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA.
Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.
Int Immunol. 8: 641-649, 1996. [Journal]
151)  Roberts CG, Meister GE, Jesdale BM, Lieberman J, Berzofsky JA, De Groot AS.
Prediction of HIV peptide epitopes by a novel algorithm.
AIDS Res Hum Retroviruses. 12: 593-610, 1996. [Journal]
152)  Shirai M, Kurokohchi K, Pendleton CD, Arichi T, Boyd LF, Takahashi H, Margulies DH, Berzofsky JA.
Reciprocal cytotoxic T lymphocyte cross-reactivity interactions between two major epitopes within HIV-1 gp160.
J Immunol. 157: 4399-4411, 1996. [Journal]
153)  Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA.
Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL.
J Exp Med. 184: 485-492, 1996. [Journal]
154)  Alexander-Miller MA, Leggatt GR, Berzofsky JA.
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
Proc Natl Acad Sci U S A. 93: 4102-4107, 1996. [Journal]
155)  Huang X, Smith MC, Berzofsky JA, Barchi JJ.
Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue.
FEBS Lett. 393: 280-286, 1996. [Journal]
156)  Kullberg MC, Berzofsky JA, Jankovic DL, Barbieri S, Williams ME, Perlmann P, Sher A, Troye-Blomberg M.
T cell-derived IL-3 induces the production of IL-4 by non-B, non-T cells to amplify the Th2-cytokine response to a non-parasite antigen in Schistosoma mansoni-infected mice.
J Immunol. 156: 1482-1489, 1996. [Journal]
157)  Shirai M, Chen M, Arichi T, Masaki T, Nishioka M, Newman M, Nakazawa T, Feinstone SM, Berzofsky JA.
Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines.
J Infect Dis. 173: 24-31, 1996. [Journal]
158)  Kurokohchi K, Akatsuka T, Pendleton CD, Takamizawa A, Nishioka M, Battegay M, Feinstone SM, Berzofsky JA.
Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.
J Virol. 70: 232-240, 1996. [Journal]
159)  Berzofsky J, Okazaki T, inventor; DHHS, assignee.
An Epitope-enhanced Vaccine Peptide To Stimulate Helper T-cells Against HIV-1 Infection.
Patent Pending, Filed in 2004. Application No. 11/579,230. Pending [Patent]
160)  Berzofsky J, Helman L, Mackall C, Van Den Broeke L, inventor; DHHS, assignee.
Immunogenic Peptides And Methods Of Use For Treating And Preventing Cancer.
Patent Pending, Filed in 2005. Application No. 12/092,449. Pending [Patent]
161)  Berzofsky J, Oh S, Pastan I, inventor; DHHS, assignee.
Immunogenic Peptides For The Treatment Of Prostate And Breast Cancer.
Patent Pending, Filed in 2003. Application No. 10/559,329. Pending [Patent]
162)  Zhu Q, Berzofsky J, inventor; DHHS, assignee.
Immunostimulatory Combinations of TLR Ligands and Methods of Use.
Patent Pending, Filed in 2007. Application No. 60/995,212. Pending [Patent]
163)  Berzofsky J, Donaldson D, Matsui S, Noben N, Paul W, Terabe M, inventor; DHHS, assignee.
Method And Composition For Inhibition Of Tumor Growth And Enhancing An Immune Response.
Patent Pending, Filed in 2001. Application No. 09/693,600. Pending [Patent]
164)  Khleif S, Berzofsky J, inventor; DHHS, assignee.
Methods And Compositions For Co-stimulation Of Immunological Responses To Peptide Antigens.
Patent Pending, Filed in 2000. Application No. 09/810,310. Pending [Patent]
165)  Khleif S, Berzofsky J, Qian J, inventor; DHHS, assignee.
Methods And Compositions For Producing An Enhanced Immune Response To A Human Papillomavirus Immunogen.
Patent Pending, Filed in 2005. Application No. 11/918,557. Pending [Patent]
166)  Berzofsky J, Matsui S, Terabe M, inventor; DHHS, assignee.
Methods To Prevent Tumor Recurrence By Blockade Of TGF-beta.
Patent Pending, Filed in 2002. Application No. 10/532,374. Pending [Patent]
167)  Berzofsky J, Oh S, Perera L, Waldmann T, inventor; DHHS, assignee.
Recombinant Vaccinia Viruses Expressing Il-15 And Methods Of Using Same.
Patent Pending, Filed in 2002. Application No. 10/538,974. Pending [Patent]
168)  Terabe M, Berzofsky J, Takaku S, inventor; DHHS, assignee.
Synergistic Effect Of TGF-beta Blockade And Immunogenic Agents On Tumors.
Patent Pending, Filed in 2005. Application No. 11/816,410. Pending [Patent]
169)  Strober W, Fichtner-Feigl S, Terabe M, Kitani A, Fuss I, Berzofsky J, inventor; DHHS, assignee.
Treatment Of Primary Tumors and Tumor Metastases with TNF-alpha Antagonists.
Patent Pending, Filed in 2007. Application No. 60/962,668. Pending [Patent]
170)  Shearer G, Berzofsky J, Brown E, Celli S, Degroot A, Grene E, Newton D, inventor; DHHS, assignee.
Use Of Semi-allogeneic Cell Line-peptide Complexes To Generate Peptide Specific T Cell Responses For Aids Immunotherapy.
Patent Pending, Filed in 1999. Application No. 09/254,556. Pending [Patent]
171)  Berzofsky J, Ahlers J, Pendleton C, Nara P, Shirai M, inventor; DHHS, assignee.
Composite synthetic peptide construct eliciting neutralizing antibodies and cytotoxic T lymphocytes against HIV.
US Patent: 5,932,218. 1999. [Patent]
172)  Khleif S, Berzofsky J, inventor; DHHS, assignee.
Human Papilloma Virus Immunogenic Peptides.
US Patent: 7,189,513. 2007. [Patent]
173)  Berzofsky J, Shirai M, Akatsuka T, Feinstone S, inventor; DHHS, assignee.
Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells.
US Patent: 5,980,899. 1999. [Patent]
174)  Berzofsky J, Kurata A, inventor; DHHS, assignee.
Immunodominant Sites of HTLV-I Envelope Protein.
US Patent: 5, 695,762. 1997. [Patent]
175)  Berzofsky J, Kurata A, inventor; DHHS, assignee.
Immunodominant sites of HTLV-I envelope protein.
US Patent: 5,622,703. 1997. [Patent]
176)  Good M, Berzofsky J, Miller L, inventor; DHHS, assignee.
Malarial immunogen.
US Patent: 4,886,782. 1989. [Patent]
177)  Berzofsky J, Kurata A, inventor; DHHS, assignee.
Method of evaluating HTLV-I-specific T cell responses.
US Patent: 5,882,853. 1999. [Patent]
178)  Berzofsky J, Kawamura H, inventor; DHHS, assignee.
Method of producing immune response.
US Patent: 5,283,323. 1994. [Patent]
179)  Berzofsky J, Takahashi H, Germain R, inventor; DHHS, assignee.
Method to induce cytotoxic T lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides.
US Patent: 5,820,865. 1998. [Patent]
180)  Berzofsky J, Takahashi H, Germain R, inventor; DHHS, assignee.
Method to induce cytotoxic T lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides.
US Patent: 5,711,947. 1998. [Patent]
181)  Bersofsky J, Sarobe P, Feinstone S, Major M, inventor; DHHS, assignee.
Modified HCV peptide immunogens.
US Patent: 7,341,726. 2008. [Patent]
182)  Berzofsky J, Feinstone S, Major M, Sarobe P, inventor; DHHS, assignee.
Modified HCV peptide vaccines.
US Patent: 7,074,410. 2006. [Patent]
183)  Berzofsky J, Sarobe P, Major M, Feinstone S, inventor; DHHS, assignee.
Modified HCV peptide vaccines.
US Patent: 6,685,944. 2004. [Patent]
184)  Berzofsky J, Belyakov I, Derby M, Kelsall B, Strober W, inventor; DHHS, assignee.
Mucosal cytotoxic T lymphocyte.
US Patent: 6,749,856. 2004. [Patent]
185)  Berzofsky J, inventor; DHHS, assignee.
Multideterminant peptide antigens.
US Patent: 5,939,074. 1999. [Patent]
186)  Berzofsky J, Ahlers J, Pendleton C, Nara P, Shirai M, inventor; DHHS, assignee.
Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1.
US Patent: 6,294,322. 2001. [Patent]
187)  Berzofsky J, Ahlers J, Pendleton C, Nara P, Shirai M, inventor; DHHS, assignee.
Multideterminant peptides that elicit helper T-lymphocyte, cytotoxic T lymphocyte and neutralizing antibody responses against HIV-1.
US Patent: 6,214,347. 2001. [Patent]
188)  Goletz T, Berzofsky J, Helman L, inventor; DHHS, assignee.
Novel immunotherapeutic methods and vaccines.
US Patent: 5,997,869. 1999. [Patent]
189)  Berzofsky J, Hosmalin A, Clerici M, Germain R, Shearer G, Moss B, Pendleton C, inventor; DHHS, assignee.
Peptides stimulating cytotoxic T cells immune to HIV RT.
US Patent: 5,336,758. 1994. [Patent]
190)  Berzofsky J, Ahlers J, Pendleton C, Nara P, Shirai M, inventor; DHHS, assignee.
Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipients.
US Patent: 7,094,405. 2006. [Patent]
191)  Berzofsky J, Takeshita T, Shirai M, Pendleton C, Kozlowski S, Margulies D, inventor; DHHS, assignee.
Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope.
US Patent: 5,976,541. 1999. [Patent]
192)  Berzofsky J, Ouyang C, DeLisi C, Margalit H, Cornette J, Cease K, inventor; DHHS, assignee.
Synthetic peptides sharing sequence homology with the HIV envelope protein.
US Patent: 5,081,226. 1992. [Patent]
193)  Berzofsky J, Hale P, Hosmalin A, Margalit H, Spouge J, Cornette J, inventor; DHHS, assignee.
Synthetic vaccine against AIDS virus.
US Patent: 5,030,449. 1991. [Patent]
194)  Good M, Kumar S, Berzofsky J, Miller L, inventor; DHHS, assignee.
Synthetic vaccine against P. falciparum malaria.
US Patent: 5,028,425. 1991. [Patent]
195)  Klimpel K, Goletz T, Arora N, Leppla S, Berzofsky J, inventor; DHHS, assignee.
Targeting antigens to the MHC class I processing pathway with an Anthrax toxin fusion protein.
US Patent: 6,592,872. 2003. [Patent]
196)  Klimpel K, Goletz T, Arora N, Leppla S, Berzofsky J, inventor; DHHS, assignee.
Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein.
US Patent: 7,097,965. 2006. [Patent]

This page was last updated on 11/20/2008.